These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37041086)

  • 1. Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders.
    Volak LP; Duevel HM; Humphreys S; Nettleton D; Phipps C; Pike A; Rynn C; Scott-Stevens P; Zhang D; Zientek M
    Drug Metab Dispos; 2023 Jul; 51(7):792-803. PubMed ID: 37041086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry perspective on the nonclinical safety assessment of heterobifunctional degraders.
    Hemkens M; Stamp K; Loberg LI; Moreau K; Hart T
    Drug Discov Today; 2023 Aug; 28(8):103643. PubMed ID: 37244567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key Considerations in Targeted Protein Degradation Drug Discovery and Development.
    Qin L; Dai H; Wang J
    Front Chem; 2022; 10():934337. PubMed ID: 35978859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS delivery of targeted protein degraders.
    Agarwal P; Reid DL; Amiji M
    J Control Release; 2024 Aug; 372():661-673. PubMed ID: 38936742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Protein Degraders- The Druggability Perspective.
    Singh S; Srivastava P
    J Pharm Sci; 2024 Mar; 113(3):539-554. PubMed ID: 37926234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of machine learning models for property prediction to targeted protein degraders.
    Peteani G; Huynh MTD; Gerebtzoff G; Rodríguez-Pérez R
    Nat Commun; 2024 Jul; 15(1):5764. PubMed ID: 38982061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.
    Bolleddula J; Brady K; Bruin G; Lee A; Martin JA; Walles M; Xu K; Yang TY; Zhu X; Yu H
    Drug Metab Dispos; 2022 Jun; 50(6):837-845. PubMed ID: 35149541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fundamental aspects of DMPK optimization of targeted protein degraders.
    Cantrill C; Chaturvedi P; Rynn C; Petrig Schaffland J; Walter I; Wittwer MB
    Drug Discov Today; 2020 Jun; 25(6):969-982. PubMed ID: 32298797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development.
    Cooper MS; Norley MC; Armitage S; Cresser-Brown JO; Edmonds AK; Goggins S; Hopewell JP; Karadogan B; Knights KA; Nash TJ; Oakes CS; O'Neill WJ; Pridmore SJ; Maple HJ; Marsh GP
    Org Biomol Chem; 2023 Oct; 21(41):8344-8352. PubMed ID: 37800999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging mechanisms of targeted protein degradation by molecular glues.
    Frere GA; de Araujo ED; Gunning PT
    Methods Cell Biol; 2022; 169():1-26. PubMed ID: 35623698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods.
    Mostofian B; Martin HJ; Razavi A; Patel S; Allen B; Sherman W; Izaguirre JA
    J Chem Inf Model; 2023 Sep; 63(17):5408-5432. PubMed ID: 37602861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space.
    Poongavanam V; Doak BC; Kihlberg J
    Curr Opin Chem Biol; 2018 Jun; 44():23-29. PubMed ID: 29803972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space.
    Caron G; Kihlberg J; Goetz G; Ratkova E; Poongavanam V; Ermondi G
    ACS Med Chem Lett; 2021 Jan; 12(1):13-23. PubMed ID: 33488959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted protein degradation: Emerging concepts and protein state-specific targeting principles.
    Tao AJ; Gadbois GE; Buczynski SA; Ferguson FM
    Curr Opin Chem Biol; 2022 Apr; 67():102114. PubMed ID: 35042023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models.
    Moda TL; Torres LG; Carrara AE; Andricopulo AD
    Bioinformatics; 2008 Oct; 24(19):2270-1. PubMed ID: 18684738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on the development of first-in-class protein degraders.
    Rambacher KM; Calabrese MF; Yamaguchi M
    Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degraders early developability assessment: face-to-face with molecular properties.
    Ermondi G; Vallaro M; Caron G
    Drug Discov Today; 2020 Sep; 25(9):1585-1591. PubMed ID: 32565163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.